BC
CERE

Brookfield Corp’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Brookfield Corp’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-43,204
Closed -$1.27M – 760
2021
Q3 		$1.27M Buy
43,204
+13,690
+46% +$384K 0.01% 403
2021
Q2 		$756K Buy
29,514
+5,261
+22% +$75.3K ﹤0.01% 489
2021
Q1 		$333K Sell
24,253
-12,102
-33% -$177K ﹤0.01% 434
2020
Q4 		$603K Buy
+36,355
New +$472K ﹤0.01% 401

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Brookfield Corp's CERE Position: Q4 2021 in Review

Brookfield Corp sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q4 2021, closing a stake of 43,204 shares — an estimated $1.27M sold.

Brookfield Corp first reported a position in CERE in Q4 2020 and held it in 4 quarters. The position peaked at $1.27M in Q3 2021. 107 funds tracked by Wall St. Rank hold CERE as of Q4 2021.

  • Brookfield Corp reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Brookfield Corp sold 43,204 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q4 2021, an estimated $1.27M.
  • Brookfield Corp first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
  • Brookfield Corp's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.27M in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q4 2021.

Based on Brookfield Corp's 13F filing for Q4 2021, filed 14 Feb 2022.